MedTrace Logo

Booster Dose of sIPV Co-administered With MMR and HepA-I.

NCT06442449 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 889

Last updated 2026-01-16

No results posted yet for this study

Summary

This is an Open-labeled, Randomized, Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of Booster Dose of Sabin Strain Inactivated Poliovirus Vaccine (Vero cell) (sIPV) Co-administered with Measles, Mumps, Rubella (MMR) Combined Live Attenuated Vaccine and Inactivated Hepatitis A (Hep-A) Vaccine.

Conditions

  • Poliomyelitis

Interventions

BIOLOGICAL

MMR

vaccination with MMR

BIOLOGICAL

HepA-I

vaccination with HepA-I

BIOLOGICAL

sIPV

vaccination with sIPV

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Pan Hongxing · Jiangsu Center for Disease Control and Prevention (Jiangsu Institute of Public Health)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Months
Max Age
22 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-08
Primary Completion
2025-09-10
Completion
2025-10-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06442449 on ClinicalTrials.gov